Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation
Lung cancer [LC] is the leading cause of cancer death worldwide. The standard treatment of locally advanced lung cancer unresectable or marginally resectable is combination therapy with radical or preoperative chemoradiation. The local control rates and survival with this treatment modality have increased by more than 30%. Radiotherapy [RT] with technical molded 3D [3D-CRT, Three-Dimensional Conformal Radiation Therapy] or IMRT [intensity-modulated radiation therapy] has allowed that the total dose of radiation has increased which leads to a direct benefit on the results treatment.
Between 17-30% of patients are susceptible to pneumonitis due to radiation [NR]. This complication may appear at the end of the RT or up to 6 months after the treatment. In severe cases, mortality can reach 50%.
It's well known that in various diseases, functional abnormalities precede the clinical manifestations. The degree of pulmonary failure secondary to RT is measured following the standards of the Radiation Therapy Oncology Group who ranks in degrees [0 to 4].
Not precisely known factors that influence the development of NR.
Radiation; Adverse Effect, Pneumonitis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Clinical, Biochemical, Dosimetric and Functional Respiratory Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer (Stages IIIa and IIIb) Treated With Chemotherapy and Radiotherapy|
- Evaluate pulmonary function after chemoradiation treatment in locally advanced NSCLC patients. [ Time Frame: January 2012 to December 2014 ] [ Designated as safety issue: No ]
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
locally advanced lung cancer
Patients with locally advanced lung cancer who are candidates to chemoradiation
To evaluate the effect of chemotherapy and thoracic radiotherapy on pulmonary function and identify predictors of radiation pneumonitis in locally advanced lung cancer [stages IIIA and IIIB].
Respiratory function tests may predict the development of radiation pneumonitis in patients with locally advanced lung cancer who receive radical treatment with chemoradiation.
Methods Prospective cohort study with patients with locally advanced lung cancer of the Lung Cancer Clinic of the National Cancer Institute [INCAN]. Patients will receive weekly paclitaxel 50 mg and carboplatin AUC 2 with concomitant radiotherapy 44-63 Gy (22-33 fractions). Followup of lung function tests at baseline, during treatment with radiotherapy and will be carried out on 4 more occasions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01580579
|Contact: Oscar G. Arrieta Rodriguez, MDfirstname.lastname@example.org|
|Contact: Jorge A. Alatorre Alexander, MDemail@example.com|
|Instituto Nacional de Cancerología de México||Recruiting|
|Mexico city, Mexico, 14000|
|Contact: Oscar G. Arrieta Rodriguez, MD 00525532236247 firstname.lastname@example.org|
|Contact: Jorge A. Alatorre Alexander, MD 00525529002732 email@example.com|
|Sub-Investigator: Luis Torre Bouscoulet, MD|
|Principal Investigator: Oscar G Arrieta Rodriguez, MD|
|Sub-Investigator: Jose R Perez Padilla, MD|
|Sub-Investigator: María C García Sancho Figueroa, MD|
|Sub-Investigator: Jorge A Alatorre Alexander, MD|
|Principal Investigator:||Oscar Arrieta, MD||Instituto de Cancerología|